Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 31, Number 2—February 2025
Dispatch

Borrelia spielmanii–Associated Neuroborreliosis in Patient Receiving Rituximab, Belgium

Timothée Carette1, Louisien Lebrun1Comments to Author , Benoît Kabamba-Mukadi, Jean-Marc Raymackers, and Jean-Louis Bayart
Author affiliation: Clinique Saint-Pierre Ottignies, Ottignies, Belgium (T. Carette, L. Lebrun, J.-M. Raymackers, J.L. Bayart); UCLouvain Institute of NeuroScience, Brussels, Belgium (L. Lebrun); UCLouvain Institut de Recherche Expérimentale et Clinique, Brussels (B. Kabamba-Mukadi); Cliniques Universitaires Saint-Luc, Brussels (B. Kabamba-Mukadi, J.-L. Bayart)

Main Article

Figure 1

Contrast-enhanced T1-weighted magnetic resonance imaging scans of spine and cauda equina in study of Borrelia spielmanii–associated neuroborreliosis in patient receiving rituximab, Belgium. Subtle intradural contrast enhancement was noted after gadolinium injection. No hypertrophy of the cauda equina was found.

Figure 1. Contrast-enhanced T1-weighted magnetic resonance imaging scans of spine and cauda equina in study of Borrelia spielmanii–associated neuroborreliosis in patient receiving rituximab, Belgium. Subtle intradural contrast enhancement was noted after gadolinium injection. No hypertrophy of the cauda equina was found.

Main Article

1These first authors contributed equally to this article.

Page created: December 11, 2024
Page updated: January 31, 2025
Page reviewed: January 31, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external